Latest Conference Articles

April 11th 2022, 8:15pm

AACR Annual Meeting

Perioperative pembrolizumab plus standard of care chemotherapy followed by adjuvant pembrolizumab showed a meaningful pathological complete response rate in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

April 11th 2022, 5:25pm

Patients with extensive-stage small cell lung cancer whose disease harbors inflamed or YAP1 molecular subtypes may be more likely to derive superior overall survival benefit from durvalumab and chemotherapy vs those with other overexpressed biomarkers.

April 11th 2022, 3:41pm

AACR Annual Meeting

The combination of nivolumab with chemotherapy elicited a higher overall survival rate compared with chemotherapy alone in patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, regardless of tumor mutational burden (TMB) status.

April 11th 2022, 1:05am

AACR Annual Meeting

The dual immunotherapy combination of nivolumab and ipilimumab elicited encouraging and durable responses with acceptable safety in patients with advanced or metastatic tumor mutational burden–high solid tumors that were refractory to standard therapies, meeting the primary end points of the phase 2 CheckMate-848 trial.

April 11th 2022, 12:40am

AACR Annual Meeting

The oral ataxia-telangiectasia and Rad3–related protein inhibitor elimusertib produced durable and prolonged responses in patients with advanced solid tumors who have ATM gene alterations and BRCA1/2 defects.

April 11th 2022, 12:01am

AACR Annual Meeting

In the ENDOLA trial, olaparib in combination with metronomic cyclophosphamide and metformin showed a significant non-progression rate in patients with recurrent advanced or metastatic endometrial cancer.

April 10th 2022, 11:49pm

AACR Annual Meeting

The T-cell attributes of axicabtagene ciloleucel impacted tumor burden, efficacy outcomes, peak levels of proinflammatory cytokines, and toxicities such as neurologic events and cytokine release syndrome in patients with relapsed/refractory large B-cell lymphoma.

April 10th 2022, 9:40pm

AACR Annual Meeting

GD2-directed CAR T-cell therapy demonstrated prolonged periods of radiographic and clinical improvement in pediatric and young adult patients with H3K27M-mutated diffuse intrinsic pontine gliomas and spinal diffuse midline gliomas.

April 10th 2022, 9:09pm

Grace Dy, MD, discusses the use of sotorasib in patients with non–small cell lung cancer with KRAS G12C mutations.

April 10th 2022, 8:47pm

AACR Annual Meeting

Off-the-shelf anti-mesothelin T-cell receptor fusion construct T cells demonstrated prolonged persistence and efficacy in vivo against mesothelin-expressing tumors in mice, compared with gavocabtagene autoleucel.

April 10th 2022, 8:39pm

AACR Annual Meeting

Sotorasib demonstrated an overall survival rate of 32.5% at 2 years in patients with KRAS G12C–mutant non–small cell lung cancer, according to longer follow-up data from the phase 1/2 CodeBreaK 100 trial.

April 10th 2022, 8:26pm

AACR Annual Meeting

Among patients with ductal carcinoma in situ, a significant portion of recurrences were not genetically related to the primary tumor.

April 10th 2022, 7:58pm

AACR Annual Meeting

The innate cell engager AMF13 combined with preactivated and expanded natural killer (NK) cells induced “very encouraging activity” in patients with heavily pretreated lymphoma.

April 8th 2022, 10:12pm

First-line pembrolizumab monotherapy continued to elicit an overall survival benefit and durable tumor response vs standard-of-care platinum-based chemotherapy in Chinese patients with untreated PD-L1–positive, advanced or metastatic non–small cell lung cancer without sensitizing EGFR or ALK mutations.

April 8th 2022, 9:10pm

AACR Annual Meeting

Temferon, genetically modified Tie2-expressing monocytes targeting interferona2, showed the potential to activate the immune system and reprogram the tumor microenvironment in patients with glioblastoma.

April 6th 2022, 4:00pm

Selecting the optimal frontline treatment regimen for patients with unresectable metastatic colorectal cancer requires careful consideration of multiple patient and treatment characteristics.

April 1st 2022, 6:45pm

The expansion of the treatment armamentarium has emphasized the importance of genetic testing in patients with metastatic colorectal cancer, according to Christopher Lieu, MD, who added continued developments in the field have produced additional treatment regimens across patient subsets.

April 1st 2022, 6:22pm

School of Gastrointestinal Oncology

Distinctions in histology, molecular profiles, and tumor location have set diverging course of care for the treatment of patients with gastrointestinal cancers.

March 20th 2022, 6:31pm

SGO Annual Meeting

When maintenance niraparib was administered at an individualized starting dose, it resulted in a statistically significant and clinically meaningful improvement in progression-free survival vs placebo in patients with newly diagnosed ovarian cancer, irrespective of biomarker status.

March 20th 2022, 5:40pm

SGO Annual Meeting

Maintenance selinexor monotherapy was found to improve progression-free survival over placebo in patients with advanced or recurrent endometrial cancer.